Advertisement

Topics

Trimeris, Inc. Company Profile

11:31 EST 22nd November 2017 | BioPortfolio

Trimeris, Inc. (Nasdaq: TRMS) is a biopharmaceutical company engaged in the commercialization of therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. FUZEON®, approved in the U.S., Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. For more information about Trimeris, please visit the Company's website at http://www.trimeris.com.


News Articles [1 Associated News Articles listed on BioPortfolio]

PTV News: Oct 6, 2009

Top stories on October 6th, 2009: Sanofi launch generic of their own drug Plavix Trimeris sold to Arigene for $81M Sandoz CEO: 10 new drugs a year in Japan CBR Pharma Insights on ‘lifecycle...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Trimeris, Inc.

Trimeris, Inc. (Nasdaq: TRMS) is a biopharmaceutical company engaged in the commercialization of therapeutic agents for the treatment of viral disease. The core technology platfor...

Trimeris

Based in Morrisville, North Carolina, Trimeris was founded in 1993 by leading researchers in the study of the human immunodeficiency virus (HIV). Their work in the early 1990s led to a breakthrough in...

More Information about "Trimeris, Inc." on BioPortfolio

We have published hundreds of Trimeris, Inc. news stories on BioPortfolio along with dozens of Trimeris, Inc. Clinical Trials and PubMed Articles about Trimeris, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Trimeris, Inc. Companies in our database. You can also find out about relevant Trimeris, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record